Home > Publications Database > Neurobildgebung mit SPECT und PET in Deutschland: Ergebnisse der 1. Umfrage zur nuklearmedizinischen Neurobildgebung in Deutschland 2023. > print

001     280229
005     20250822101711.0
024 7 _ |a 10.1055/a-2566-1487
|2 doi
024 7 _ |a pmid:40233814
|2 pmid
024 7 _ |a pmc:PMC12328034
|2 pmc
024 7 _ |a 0029-5566
|2 ISSN
024 7 _ |a 2567-6407
|2 ISSN
037 _ _ |a DZNE-2025-00907
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Buchert, Ralph
|0 0000-0002-0945-0724
|b 0
245 _ _ |a Neurobildgebung mit SPECT und PET in Deutschland: Ergebnisse der 1. Umfrage zur nuklearmedizinischen Neurobildgebung in Deutschland 2023.
260 _ _ |a Stuttgart
|c 2025
|b Thieme
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1754898185_31915
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The advent of disease-modifying therapies for neurodegenerative diseases may result in a growing demand for nuclear neuroimaging procedures presenting opportunities but also challenges to the nuclear medicine community. Whether capacity and expertise in Germany are sufficient to meet an increasing demand for nuclear neuroimaging is under discussion. Against this background, the Neuroimaging Working Group of the German Society of Nuclear Medicine initiated the first survey on the status of nuclear neuroimaging in Germany in 2023. 82 institutions participated in the survey: 33 practices, 15 community hospitals, 34 university hospitals. Primary findings were the following. In practices, brain scans are less frequently performed than in hospitals and are often limited to dopamine transporter SPECT. Brain PET is mainly performed in hospitals, and in community hospitals it is often restricted to FDG PET. Nevertheless, availability of amyloid PET with well-certified quality can be taken for granted. Thus, access to amyloid PET will not be a major bottleneck for new treatments of Alzheimer's disease. Adequate reimbursement and clear anchoring in clinical guidelines have the greatest potential to advance nuclear neuroimaging in Germany. Clinical dopamine transporter SPECT is largely in agreement with procedure guidelines. An area for improvement is the limited availability of MR images to avoid misinterpretation of structural/vascular lesions as nigrostriatal degeneration. The survey provides the first systematic assessment of the status of nuclear neuroimaging in Germany. It underscores the capacity of the German nuclear medicine community to meet an increasing demand for neuroimaging procedures, its adherence to procedure guidelines and identifies topics for improvement.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Germany
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Tomography, Emission-Computed, Single-Photon: statistics & numerical data
|2 MeSH
650 _ 2 |a Positron-Emission Tomography: statistics & numerical data
|2 MeSH
650 _ 2 |a Neuroimaging: statistics & numerical data
|2 MeSH
650 _ 2 |a Neuroimaging: methods
|2 MeSH
650 _ 2 |a Surveys and Questionnaires
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
700 1 _ |a Drzezga, Alexander
|0 P:(DE-2719)2811239
|b 1
|e First author
|u dzne
700 1 _ |a Schreckenberger, Mathias
|b 2
700 1 _ |a Langen, Karl Josef
|b 3
700 1 _ |a Meyer, Philipp T
|b 4
700 1 _ |a Medicine, Working Group Nuclear Neuroimaging of the German Society of Nuclear
|b 5
|e Collaboration Author
773 _ _ |a 10.1055/a-2566-1487
|g Vol. 64, no. 4, p. 250 - 261
|0 PERI:(DE-600)2030804-8
|n 4
|p 250 - 261
|t Nuklearmedizin
|v 64
|y 2025
|x 0029-5566
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/280229/files/DZNE-2025-00907.pdf
856 4 _ |u https://pub.dzne.de/record/280229/files/DZNE-2025-00907%20SUP.pdf
856 4 _ |u https://pub.dzne.de/record/280229/files/DZNE-2025-00907%20SUP.pdf?subformat=pdfa
|x pdfa
856 4 _ |u https://pub.dzne.de/record/280229/files/DZNE-2025-00907.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:280229
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2811239
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1011202
|k AG Boecker
|l Positron Emissions Tomography (PET)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011202
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21